Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320015 | 0.81 | VCAM1 (0.51) | VCAM1MAPTLMNAPKMKAT2B | |
| SCHEMBL31432406 | 0.81 | VCAM1 (0.51) | VCAM1MAPTLMNAPKMKAT2B | |
| SCHEMBL25784409 | 0.79 | TSHR (0.53) | MAPTKAT2BALDH1A1SMN1; SMN2SIGMAR1 | |
| SCHEMBL23861124 | 0.78 | TSHR (0.50) | MAPTHTR6LMNAPKMALDH1A1 | |
| SCHEMBL30060723 | 0.78 | TSHR (0.50) | MAPTHTR6LMNAPKMALDH1A1 | |
| SCHEMBL9195710 | 0.77 | VCAM1 (0.54) | VCAM1MAPTLMNAPKMKAT2B | |
| SCHEMBL14681249 | 0.77 | VCAM1 (0.54) | VCAM1MAPTLMNAPKMKAT2B | |
| SCHEMBL249183 | 0.77 | VCAM1 (0.54) | VCAM1MAPTSLC6A4LMNAPKM | |
| SCHEMBL6382390 | 0.75 | ALDH3A1 (0.51) | VCAM1MAPTLMNAALDH1A1HPGD | |
| SCHEMBL6426528 | 0.75 | ALDH1A1 (0.43) | MAPTHRH3ALDH1A1SMN1; SMN2SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464269-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE | CHIESI FARM SPA (IT) | 2020-04-01 | — | — | EP | disclosed |
| EP-3464269-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017207433-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-01 | — | — | WO | disclosed |
| US-9862706-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-09 | — | — | US | disclosed |
| US-9862706-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-09 | — | — | US | disclosed |
| WO-2017207433-A1 | HETETOCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342056-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | VCAM1 337/4885MAPT 4326/4885HTR6 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.